ReviewEndocrine pathology2023
Diagnostic, Prognostic, and Predictive Role of Ki67 Proliferative Index in Neuroendocrine and Endocrine Neoplasms: Past, Present, and Future.
Review in Endocrine pathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 84 citations in OpenAlex.
- Microenvironment-responsive injectable marine polysaccharide hydrogel empowered by bimetallic MOF nanozymes for in situ pancreatic cancer immunotherapyMaterials today. Bio · 2026Article
- Renal Neuroendocrine Tumor Mimicking Upper Tract Urothelial Carcinoma.IJU case reports · 2026Article
- Multiple skin and subcutaneous metastasis as initial manifestation in neuroendocrine carcinoma lung: A rare case report.Radiology case reports · 2026Article
- Article
- Integrating Digital Ki-67 Labeling Index and K-TIRADS for Malignancy Risk Stratification in Thyroid Core Needle Biopsies.Cancers · 2026Article
- Development and internal validation of a SEER-based prediction model for survival in poorly and undifferentiated colorectal neuroendocrine neoplasms.Translational cancer research · 2026Article
- The GAPP Aggressivity Score Correlates with Total Enriched Somatic Variant Burden in Sporadic Pheochromocytoma-A Pilot Study.Cancers · 2026Article
- Article
- Primary testicular neuroendocrine tumor: Diagnostic challenges and WHO 2022 classification insights.The Journal of international medical research · 2026Article
- Melatonin-selenium nanoformulation: a promising therapeutic strategy against Ehrlich ascites carcinoma.Scientific reports · 2026Article
- Tumor biology versus nodal stage in predicting survival after resection of pulmonary atypical carcinoids.Updates in surgery · 2026Article
- DNA methylation profiling predicts postsurgical regrowth in SF1-lineage nonfunctioning pituitary neuroendocrine tumors.Neuro-oncology · 2026Article
- Revisiting Ki-67 Assessment in Canine Mast Cell Tumours: From Manual Hotspot to Automated Global Analysis.Veterinary sciences · 2026Article
- CT-based radiomics nomogram for preoperative prediction of Ki-67 in lung neuroendocrine neoplasms: a multicenter study.BMC medical imaging · 2026Article
- Chebulagic acid targets FBXO38 to enhance natural killer cell-mediated anti-tumor immunity in lung adenocarcinoma.Human cell · 2026Article
- State of the Art on Thyroid Cancer Biology and Oncology.Biomedicines · 2026Review
- Ultrasound-based radiomics and habitat analysis for noninvasive assessment of Ki-67 overexpression in breast cancer.Frontiers in oncology · 2026Article
- Avoiding overdiagnosis of parathyroid carcinoma.Virchows Archiv : an international journal of pathology · 2026Review
- Clinicopathological Spectrum and Survival in Esophageal Neuroendocrine Carcinoma and Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms: A 74-Patient Cohort.Cancer management and research · 2026Article
- Neuroendocrine Neoplasms of the Gastrointestinal Tract: Morphology, WHO 2022 Grading, and Prognostic Perspectives.Cureus · 2026Review
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of Ki67 immunohistochemistry in the work-up of neuroendocrine neoplasms (NENs) has opened a new approach for their diagnosis and prognostic evaluation. Since the first demonstration of the prognostic role of Ki67 proliferative index in pancreatic NENs in 1996, several studies have been performed to explore its prognostic, diagnostic, and predictive role in other neuroendocrine and endocrine neoplasms. A large amount of information is now available and published results globally indicate that Ki67 proliferative index is useful to this scope, although some differences exist in relation to tumor site and type. In gut and pancreatic NENs, the Ki67 proliferative index has a well-documented and accepted diagnostic and prognostic role and its evaluation is mandatory in their diagnostic work-up. In the lung, the Ki67 index is recommended for the diagnosis of NENs on biopsy specimens, but its diagnostic role in surgical specimens still remains to be officially accepted, although its prognostic role is now well documented. In other organs, such as the pituitary, parathyroid, thyroid (follicular cell-derived neoplasms), and adrenal medulla, the Ki67 index does not play a diagnostic role and its prognostic value still remains a controversial issue. In medullary thyroid carcinoma, the Ki67 labelling index is used to define the tumor grade together with other morphological parameters, while in the adrenal cortical carcinoma, it is useful to select patients to treated with mitotane therapy. In the present review, the most important information on the diagnostic, prognostic, and predictive role of Ki67 proliferative index is presented discussing the current knowledge. In addition, technical issues related to the evaluation of Ki67 proliferative index and the future perspectives of the application of Ki67 immunostaining in endocrine and neuroendocrine neoplasms is discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.